Complete financial analysis of Repligen Corporation (RGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Repligen Corporation, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Jenkem Technology Co., Ltd. (688356.SS) Income Statement Analysis – Financial Results
- Lithium South Development Corporation (LIS.V) Income Statement Analysis – Financial Results
- USEN-NEXT HOLDINGS Co.,Ltd. (9418.T) Income Statement Analysis – Financial Results
- Hitachi Energy India Limited (POWERINDIA.NS) Income Statement Analysis – Financial Results
- Taisho Pharmaceutical Holdings Co., Ltd. (4581.T) Income Statement Analysis – Financial Results
Repligen Corporation (RGEN)
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 638.76M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M | 68.17M | 62.27M | 27.29M | 20.97M | 29.36M | 19.30M | 14.07M | 12.91M | 9.36M | 6.91M | 7.77M | 4.30M | 2.35M | 3.45M | 2.60M | 2.40M | 3.80M | 10.90M | 16.90M | 26.80M | 27.30M | 11.70M | 7.60M | 12.70M | 8.50M | 10.20M | 3.70M | 3.60M |
| Cost of Revenue | 323.54M | 345.83M | 279.28M | 156.63M | 119.10M | 85.95M | 67.05M | 47.12M | 35.25M | 28.02M | 25.16M | 27.17M | 7.12M | 5.51M | 6.78M | 6.16M | 3.61M | 3.55M | 3.89M | 3.25M | 3.48M | 1.99M | 1.12M | 782.23K | 400.00K | 300.00K | 300.00K | 100.00K | -1.10M | 1.50M | -500.00K | -200.00K | -600.00K | 10.50M | 7.60M | 7.20M | 4.40M | 2.60M |
| Gross Profit | 315.23M | 455.71M | 391.25M | 209.63M | 151.15M | 108.08M | 74.19M | 57.42M | 48.29M | 35.53M | 43.01M | 35.10M | 20.17M | 15.46M | 22.58M | 13.14M | 10.46M | 9.36M | 5.47M | 3.67M | 4.29M | 2.31M | 1.22M | 2.67M | 2.20M | 2.10M | 3.50M | 10.80M | 18.00M | 25.30M | 27.80M | 11.90M | 8.20M | 2.20M | 900.00K | 3.00M | -700.00K | 1.00M |
| Gross Profit Ratio | 49.35% | 56.85% | 58.35% | 57.23% | 55.93% | 55.70% | 52.53% | 54.93% | 57.80% | 55.90% | 63.09% | 56.36% | 73.92% | 73.74% | 76.92% | 68.08% | 74.32% | 72.50% | 58.47% | 53.02% | 55.22% | 53.67% | 52.15% | 77.33% | 84.62% | 87.50% | 92.11% | 99.08% | 106.51% | 94.40% | 101.83% | 101.71% | 107.89% | 17.32% | 10.59% | 29.41% | -18.92% | 27.78% |
| Research & Development | 42.72M | 43.94M | 34.27M | 20.18M | 19.45M | 15.77M | 8.67M | 7.36M | 5.74M | 5.61M | 7.34M | 10.49M | 12.53M | 14.16M | 12.77M | 7.24M | 5.92M | 5.16M | 5.04M | 6.48M | 5.23M | 5.36M | 5.79M | 3.75M | 1.80M | 1.40M | 1.40M | 12.30M | 31.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 65.69M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 0.00 | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 631.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 218.11M | 215.83M | 183.87M | 119.62M | 95.61M | 66.32M | 51.51M | 30.85M | 24.70M | 17.15M | 12.70M | 13.23M | 8.02M | 7.07M | 5.93M | 10.17M | 6.36M | 5.42M | 4.60M | 4.71M | 4.16M | 2.53M | 2.49M | 2.48M | 1.60M | 1.30M | 2.40M | 4.90M | 4.70M | 42.10M | 37.40M | 23.60M | 15.60M | 3.90M | 3.70M | 3.60M | 3.60M | 3.00M |
| Other Expenses | 0.00 | -9.53M | -1.17M | -214.00K | -314.00K | 262.00K | -687.00K | -860.00K | -445.00K | 188.00K | -110.65K | 26.40K | 1.54B | 1.35M | 1.09M | -40.17M | 0.00 | 0.00 | 0.00 | 2.41M | 0.00 | 0.00 | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| Operating Expenses | 261.12M | 259.77M | 218.14M | 139.80M | 115.06M | 82.09M | 60.18M | 38.21M | 30.44M | 22.76M | 20.04M | 23.72M | 20.55M | 21.23M | 18.70M | -22.76M | 12.28M | 10.58M | 9.63M | 13.61M | 9.39M | 7.89M | 8.56M | 6.56M | 3.70M | 2.90M | 4.00M | 18.60M | 38.30M | 44.50M | 39.10M | 24.70M | 16.50M | 4.70M | 4.30M | 4.10M | 4.20M | 3.50M |
| Cost & Expenses | 584.66M | 605.60M | 497.42M | 296.44M | 234.16M | 168.04M | 127.23M | 85.33M | 65.69M | 50.79M | 45.21M | 50.89M | 27.67M | 26.74M | 25.48M | -16.60M | 15.90M | 14.13M | 13.52M | 16.86M | 12.87M | 9.88M | 9.68M | 7.34M | 4.10M | 3.20M | 4.30M | 18.70M | 37.20M | 46.00M | 38.60M | 24.50M | 15.90M | 15.20M | 11.90M | 11.30M | 8.60M | 6.10M |
| Interest Income | 0.00 | 6.98M | 176.00K | 1.74M | 5.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 10.03M | 1.16M | 12.71M | 12.13M | 9.29M | 6.71M | 6.44M | 3.77M | 32.00K | 49.96K | 49.85K | 56.71K | 26.17K | 1.97K | 2.96K | 2.96K | 0.00 | 696.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 300.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 68.56M | 50.99M | 38.45M | 27.07M | 20.87M | 15.78M | 10.45M | 5.33M | 4.59M | 4.02M | 3.11M | 3.51M | 1.67M | 1.38M | 1.08M | 824.63K | 539.03K | 398.43K | 756.26K | 886.71K | 802.23K | 257.54K | 276.85K | 324.41K | 300.00K | 200.00K | 200.00K | 1.40M | 2.60M | 2.40M | 1.70M | 1.10M | 900.00K | 800.00K | 600.00K | 500.00K | 600.00K | 500.00K |
| EBITDA | 127.77M | 246.93M | 211.56M | 101.62M | 58.43M | 41.77M | 24.14M | 24.55M | 22.44M | 15.16M | 26.13M | 14.84M | -30.47K | 1.66M | -3.52M | 6.85M | 36.72M | -1.83M | -1.22M | -2.23M | -8.66M | -4.29M | -5.32M | -7.06M | -4.04M | -2.46M | -615.02K | -2.80M | -6.40M | -17.70M | -16.80M | -9.60M | -11.70M | -7.40M | -1.70M | -2.80M | -600.00K | -4.30M |
| EBITDA Ratio | 20.00% | 23.03% | 25.64% | 19.01% | 13.24% | 13.53% | 9.43% | 17.56% | 20.83% | 20.38% | 33.52% | 18.32% | 4.77% | -20.92% | 16.88% | -28.53% | -15.87% | -15.42% | -48.96% | -101.69% | -62.40% | -149.65% | -388.18% | -105.49% | -7.69% | -25.00% | -10.53% | -25.69% | -37.87% | -62.69% | -35.16% | -100.00% | -132.89% | -14.17% | -32.94% | -21.57% | 310.81% | -86.11% |
| Operating Income | 54.58M | 133.61M | 133.50M | 42.54M | 14.90M | 25.99M | 14.01M | 15.97M | 13.76M | 10.69M | 22.87M | 11.08M | -374.07K | -5.77M | 3.88M | 35.89M | -1.83M | -1.22M | -4.16M | -9.94M | -5.09M | -5.58M | -7.33M | -3.89M | -1.50M | -800.00K | -500.00K | -7.80M | -20.30M | -19.20M | -11.30M | -12.80M | -8.30M | -2.50M | -3.40M | -1.10M | -4.90M | -2.50M |
| Operating Income Ratio | 8.54% | 16.67% | 19.91% | 11.62% | 5.51% | 13.39% | 9.92% | 15.28% | 16.48% | 16.82% | 33.55% | 17.80% | -1.37% | -27.50% | 13.21% | 186.00% | -12.97% | -9.45% | -44.46% | -143.77% | -65.55% | -129.67% | -312.46% | -112.74% | -57.69% | -33.33% | -13.16% | -71.56% | -120.12% | -71.64% | -41.39% | -109.40% | -109.21% | -19.69% | -40.00% | -10.78% | -132.43% | -69.44% |
| Total Other Income/Expenses | 9.56M | -5.53M | -13.71M | -10.61M | -9.93M | -4.55M | -6.76M | -4.28M | -341.00K | 447.58K | 140.82K | -108.34K | -2.35M | 5.72M | 868.07K | 1.89M | 39.76M | 936.07K | 1.92M | 1.18B | 5.40M | 1.12M | 2.05M | 3.52M | 1.86M | 1.96M | 315.02K | 500.00K | 7.80M | 800.00K | 7.90M | 0.00 | 7.10M | 5.90M | 2.50M | 3.70M | 1.10M | 3.50M |
| Income Before Tax | 64.13M | 219.14M | 153.54M | 59.22M | 26.15M | 21.44M | 7.25M | 11.69M | 13.42M | 11.14M | 23.01M | 11.27M | -43.51K | -4.90M | 5.77M | 37.93M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Income Before Tax Ratio | 10.04% | 27.34% | 22.90% | 16.17% | 9.68% | 11.05% | 5.13% | 11.18% | 16.07% | 17.53% | 33.76% | 18.10% | -0.16% | -23.36% | 19.66% | 196.59% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| Income Tax Expense | 22.56M | 33.18M | 25.25M | -709.00K | 4.74M | 4.82M | -21.11M | 11.00K | 4.08M | 2.97M | 6.92M | -2.88M | -330.56K | -834.77K | 26.70K | 827.47K | 889.26K | -696.86K | 2.98M | 9.55M | 4.54M | 4.46M | 5.28M | 3.82M | 2.50M | 800.00K | 500.00K | 11.50M | 32.00M | 19.50M | 11.30M | 12.80M | 5.70M | 2.40M | 3.30M | -300.00K | 20.70M | 1.40M |
| Net Income | 41.58M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M | 16.09M | 14.16M | -43.51K | -4.06M | 5.75M | 37.11M | -889.26K | 696.86K | -2.98M | -9.55M | -4.54M | -4.46M | -5.28M | -3.82M | -2.50M | -800.00K | -500.00K | -11.50M | -32.00M | -19.50M | -11.30M | -12.80M | -5.70M | -2.40M | -3.30M | 300.00K | -20.70M | -1.40M |
| Net Income Ratio | 6.51% | 23.20% | 19.13% | 16.36% | 7.92% | 8.56% | 20.07% | 11.17% | 11.19% | 12.86% | 23.61% | 22.73% | -0.16% | -19.38% | 19.57% | 192.30% | -6.32% | 5.40% | -31.87% | -138.13% | -58.38% | -103.70% | -224.95% | -110.60% | -96.15% | -33.33% | -13.16% | -105.50% | -189.35% | -72.76% | -41.39% | -109.40% | -75.00% | -18.90% | -38.82% | 2.94% | -559.46% | -38.89% |
| EPS | 0.75 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 | 0.51 | 0.46 | 0.00 | -0.13 | 0.19 | 1.20 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.75 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| EPS Diluted | 0.74 | 3.24 | 2.24 | 1.11 | 0.44 | 0.37 | 0.72 | 0.34 | 0.28 | 0.25 | 0.50 | 0.45 | 0.00 | -0.13 | 0.18 | 1.18 | -0.03 | 0.02 | -0.10 | -0.32 | -0.17 | -0.17 | -0.20 | -0.18 | -0.14 | -0.05 | -0.03 | -0.74 | -2.08 | -1.53 | -0.93 | -1.14 | -0.63 | -0.31 | -0.46 | 0.04 | -3.59 | -0.47 |
| Weighted Avg Shares Out | 55.72M | 55.46M | 55.02M | 52.55M | 48.34M | 43.77M | 38.23M | 33.57M | 32.88M | 32.50M | 31.67M | 30.91M | 30.78M | 30.75M | 30.96M | 30.83M | 30.38M | 30.13M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.37M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
| Weighted Avg Shares Out (Dil) | 56.38M | 57.46M | 57.26M | 53.89M | 49.21M | 45.47M | 39.15M | 34.10M | 33.58M | 33.26M | 32.41M | 31.25M | 30.78M | 30.75M | 31.29M | 31.32M | 30.38M | 30.69M | 30.06M | 29.69M | 26.81M | 26.64M | 26.55M | 21.54M | 18.02M | 16.50M | 16.67M | 15.53M | 15.36M | 12.75M | 12.15M | 11.23M | 9.05M | 7.74M | 7.17M | 7.30M | 5.77M | 3.00M |
Sartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification
WALTHAM, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Sartorius and Repligen Corporation (NASDAQ:RGEN) today announced the launch of an integrated bioreactor system that incorporates Repligen XCell® ATF upstream intensification technology into Sartorius' Biostat STR® bioreactor, simplifying intensified seed train and...
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript
Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference...
Repligen (RGEN) Q2 Earnings Surpass Estimates
Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.91 per share a year ago.
Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year
Earnings Preview: Repligen (RGEN) Q2 Earnings Expected to Decline
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now?
Repligen to Report Second Quarter 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET
Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use products for biopharma manufacturing. The company is expected to grow...
Repligen Corporation: Not Able To Replicate The Strong Results
Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With valuations still being demanding, I am fearful of Repligen Corporation's high valuation given...
Source: https://incomestatements.info
Category: Stock Reports